Skip to content

Is misoprostol a safe alternative to manual vacuum aspiration in women with incomplete abortions in developing countries?

Is misoprostol a safe alternative to manual vacuum aspiration in women with early pregnancy failure in a low resource setting?: a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN65305620
Enrollment
180
Registered
2008-02-22
Start date
2008-02-11
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

First trimester pregnancy failure Pregnancy and Childbirth First trimester pregnancy failure

Interventions

Misoprostol 600 microgram 3 doses (one dose every 4 hours) sublingually versus MVA

Sponsors

Tanzanian German Program to Support Health (TGPSH) (Tanzania)
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. History of passage of tissue and/or blood and >30 mm endometrial thickness on TransVaginal Sonography (TVS) 2. On TVS an anembryonic gestation or fetal death with an embryonic crown-rump length between 5 and 62 mm without cardiac activity (in case of a Crown-Rump Length [CRL] of 5-9 mm TVS will be repeated after one week to ensure absence of cardiac activity) or an anembryonic gestational sac of 16-45 mm (TVS will be repeated after one week to ensure growth of the gestational sac is <3 mm and exclude a viable pregnancy)

Exclusion criteria

Exclusion criteria: 1. On TVS present fetal heart activity, a crown-rump length >62 mm, molar pregnancy or a endometrial thickness less than or equal to 30 mm 2. Fundal height of more than halfway the umbilicus and the symphysis indicating a gestational age >12 weeks 3. Known allergy to prostaglandins 4. Heavy blood loss or a pulse rate of >120/min 5. Axillary temperature of > 38°C or signs of septic abortion such as pus draining from uterus 6. Ectopic pregnancy

Design outcomes

Primary

MeasureTime frame
Ultrasonographic endometrium thickness at day 8

Secondary

MeasureTime frame
The following will be assessed at day 8: 1. Changes in hemoglobin (Hb) level 2. Side effects including pain 3. Adverse events 4. Patients satisfaction and acceptability If any problem is observed on day 8, the patient will be reviewed again on day 15 (No review at day 15 if no problem is observed).

Countries

Tanzania

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026